As regulators continue to assess the role of nicotine pouches within tobacco control frameworks, evidence on how these products are actually used over time remains limited. A recently published prospective study in Cureus helps address this gap by examining real-world patterns of nicotine pouch use across a ten-week period. The study is important not because…
Executive context Innovation in nicotine pouches has largely focused on formulation variables, nicotine strength, pH, buffering systems, flavours, and moisture content. These factors shape nicotine delivery and user perception and are central to regulatory assessment. However, a growing body of clinical, observational, and design-science evidence indicates that oral tolerability and mucosal outcomes are also strongly…
Regulation, clinical context, and evidence-based harm reduction Cigarette smoking continues to impose a disproportionate health burden in Appalachia, a region marked by persistently high smoking prevalence, elevated rates of cardiovascular disease and cancer, and long-standing socioeconomic barriers to cessation support. Despite decades of tobacco control efforts, combustible cigarette use remains entrenched in many Appalachian communities,…
Nicotine pouch performance is often discussed almost exclusively in terms of formulation. Nicotine concentration, pH, buffering systems, flavour chemistry, and moisture balance dominate both technical development and regulatory review. These elements are undeniably important. However, emerging evidence and user experience suggest that formulation alone does not fully explain how nicotine pouches are tolerated, used, or…
Youth “addiction” to nicotine pouches and other smoke-free nicotine products is increasingly invoked as a political shorthand, often without reference to how addiction is actually defined in modern clinical science. This matters, because the DSM-5 framework, the global reference standard for diagnosing substance-related disorders, does not define addiction by frequency of use alone, nor does…
As nicotine pouches gain visibility in the United States and other markets, debate around their public-health role has intensified. Much of this discussion has been driven by concern over youth uptake and regulatory uncertainty. However, recent reporting in JAMA highlights a more nuanced picture, one in which several public-health experts recognise that nicotine pouches differ…
As nicotine pouch use expands globally, regulatory debate is increasingly framed as a choice between bans and permissive access. That framing is misleading. Evidence now points toward a more effective third path: risk-proportionate regulation that shapes product design to reduce harm while preserving adult access. Nicotine pouches are neither risk-free nor uniform. Their public-health impact…
Recent media coverage of a report examining nicotine’s effects on the heart and blood vessels has renewed debate about cardiovascular risk and nicotine regulation. In response, experts contributing to the UK Science Media Centre (SMC) have provided important clarification that adds nuance often missing from public discussion. Their commentary reinforces a central principle in tobacco…
As nicotine markets continue to evolve, regulators are increasingly challenged to design policies that protect young people while also reflecting the growing body of evidence on relative risk among nicotine products. A new peer-reviewed study published in Nicotine & Tobacco Research adds important insight into how non-combustible nicotine products are used and perceived, and what…
Nicotine does have measurable effects on the cardiovascular system. That point is not in dispute. However, treating all nicotine products as equally harmful, regardless of whether they are smoked or smoke-free, is not supported by the balance of current evidence and risks undermining smoking cessation and broader public-health objectives. Recent commentary has renewed attention on…